NCT06201065 2024-01-11
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
12 trialsNCT05231382 2022-05-24
Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT04595864 2021-11-05
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Recruiting
NCT04687163 2021-01-13
Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
Sun Yat-sen University
Phase 3 Unknown
NCT02774187 2019-12-05
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT03468231 2018-03-16
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown
NCT03192618 2017-06-20
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
Phase 3 Unknown
NCT03192644 2017-06-20
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
Phase 3 Unknown
NCT02755311 2016-04-28
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT01327521 2012-06-11
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Stanford University
Phase 3 Withdrawn
NCT01489566 2011-12-14
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT00471965 2010-09-20
EACH
Sanofi
Phase 3 Completed